1. Introduction {#sec1}
===============

Although fibrosis is an essential process for the restoration and maintenance of organ integrity after injury or stress via the timely deposition of the extracellular matrix (ECM), the aberrant accumulation of stiff and disorganized ECM progressively disrupts tissue function and can ultimately cause organ failure \[[@B1]--[@B5]\]. Myocardial fibrosis is a hallmark feature of heart failure and is associated with hypertension, myocardial infarction (MI), and pathological hypertrophy followed by injury and stress \[[@B1], [@B2]\]. Systemic responses induced by the decline in systolic function, particularly neurohumoral activation (angiotensin--aldosterone system and *β*-adrenergic nervous system), are associated with the progression of heart failure (HF). Traditional therapies, such as *β*-blockers and renin-angiotensin-aldosterone system (RAAS) inhibitors, have been found to have beneficial effects in patients with cardiac fibrosis in clinical trials \[[@B6], [@B7]\]. However, these conventional drugs do not aim at directly curing myocardial fibrosis but rather aim at alleviating the underlying cardiac dysfunction mechanisms indirectly \[[@B6]\]. Therefore, great effort is currently being devoted to research on the development of therapeutic interventions for decreasing the high morbidity and mortality associated with myocardial fibrosis, particularly on the identification and modulation of its core mechanisms \[[@B1]--[@B4]\].

Despite its previous characterization as a toxic gas with a rotten egg smell, H~2~S is beginning to be associated with a growing family of gasotransmitters, with properties similar to nitric oxide (NO) and carbon monoxide (CO) \[[@B8]--[@B10]\]. As a gasotransmitter, H~2~S is involved in both the physiology and pathophysiology of the nervous, cardiovascular, and gastrointestinal systems via its antioxidant, anti-inflammatory \[[@B11]\], antinociceptive, antihypertensive, neuromodulative, and cytoprotective effects \[[@B9], [@B12]--[@B14]\]. The modulation of signals involved in myocardial fibrosis, and thereby the attenuation of pathological fibrosis, is an area of intense scientific interest due to its evident therapeutic implications for the treatment of HF \[[@B15]\]. Reduced levels of H~2~S have been identified in patients with ischemia \[[@B16]\], diabetes \[[@B17], [@B18]\], high-fat diet-induced cardiomyopathy \[[@B19]\], hypertension \[[@B20]\], and heavy metal detoxifications, such as nickel detoxification \[[@B21]\].

The role of an exogenously delivered H~2~S in antifibrosis has been identified in a variety of experimental settings ([Table 1](#tab1){ref-type="table"}). In this review, myocardial fibrosis and the potential antifibrosis effects of H~2~S are outlined. H~2~S is not the sole gasotransmitter in the body and can interact with other gasotransmitters including NO and CO. In addition to direct chemical crosstalk, NO, CO, and H~2~S compete in heme- or metal-containing proteins and at the posttranslational modification sites of proteins \[[@B9]\]. Thus, various types of crosstalk between CO, H~2~S, and NO in the cardiovascular system exist \[[@B9]\]. For example, nitrosopersulfide, polysulfides, and dinitrososulfite can be formed by the interaction of NO and H~2~S. These anionic intermediates modulate the bioavailability of NO/HNO or H~2~S/sulfane sulfur and are thus responsible for distinct physiological consequences \[[@B22]\]. Although bioactive intermediates that form interactions with each other are an emerging research field, the modulatory role of H~2~S intermediates in myocardial fibrosis is beyond our current review.

2. Hydrogen Sulfide {#sec2}
===================

2.1. Synthesis of H~2~S {#sec2.1}
-----------------------

H~2~S is the simplest thiol, which are sulfur analogs of alcohol (R-SH); is associated with the smell of rotten eggs; and has a high redox potential \[[@B23]\]. As depicted in [Figure 1](#fig1){ref-type="fig"}, H~2~S is endogenously synthesized from L-cysteine or L-homocysteine via cystathionine *β*-synthase (CBS) and cystathionine *γ*-lyase (CSE), which are pyridoxal 5′-phosphate-dependent cytosolic enzymes in the transsulfuration pathway \[[@B24]\]. CSE is involved in the cardiovascular system, especially in myocardial cells \[[@B25]\], vascular smooth muscle cells \[[@B26], [@B27]\], and endothelial cells \[[@B28]\], whereas CBS is predominantly found in the nervous system \[[@B29]\]. In the mitochondria, cysteine aminotransferase (CAT) catalyzes L-cysteine and glutamate to 3-mercaptopyruvate and *α*-ketoglutarate. Then, 3-mercaptopyruvate is metabolized to pyruvate and H~2~S via 3-mercaptopyruvate sulfurtransferase (3-MST) \[[@B23]\]. Nonenzymatically, H~2~S can also be released from preexisting intracellular sulfur stores (sulfane sulfur) through the activities of reducing agents \[[@B24], [@B30]\]. For example, the production of H~2~S from sulfur-containing amino acids (e.g., cysteine) via iron and vitamin B~6~ under physiological conditions has been found in red blood cells and tissues \[[@B31]\]. However, the exact biological roles of this nonenzymatic production of H~2~S have not yet been established.

2.2. Exogenous H~2~S {#sec2.2}
--------------------

H~2~S can be inhaled directly, and the regulated inhalation of H~2~S is an effective method for the control of hemorrhages in preclinical studies \[[@B32]\]. Although the inhalation of H~2~S gas produces few byproducts, controlling its dosage and handling the specialized equipment needed for its delivery is difficult. There are a number of compounds that have been synthesized specifically to deliver therapeutic H~2~S to tissues \[[@B9], [@B23], [@B33]\], including inorganic sulfide salts (e.g., NaHS), synthetic organic compounds with a slow H~2~S-releasing mode, conventional drug molecules coupled with an H~2~S-donating group, cysteine analogs, nucleoside phosphorothioates, and plant-derived polysulfides ([Table 1](#tab1){ref-type="table"}).

2.3. Modulation of H~2~S Level {#sec2.3}
------------------------------

The bioavailability of H~2~S inside the cell is primarily regulated by H~2~S-synthesizing enzymes (CSE, CBS, or 3-MST) and H~2~S-oxidizing enzymes located in the mitochondria (e.g., sulfide quinone reductase, persulfide dioxygenase, and thiosulfate sulfurtransferase) \[[@B9]\]. Cysteine and its derivatives can be used to boost H~2~S synthesis \[[@B33]\]. MicroRNA (miRNA) controls gene expression at the posttranscriptional level \[[@B34]\] and is one of the main factors involved in the upregulation of CSE expression \[[@B16]\]. Interestingly, currently used drugs, including angiotensin-converting enzyme (ACE) inhibitors (e.g., ramipril) \[[@B35]\], statins \[[@B36]\], calcium channel antagonists (e.g., amlodipine) \[[@B37]\], digoxin \[[@B38]\], vitamin D~3~ \[[@B39]\], aspirin \[[@B40]\], metformin \[[@B40]\], and others \[[@B23]\], may increase the production of H~2~S. For example, statins can increase H~2~S synthesis via Akt-mediated upregulation of CSE \[[@B36]\] or suppress H~2~S degradation by decreasing the concentration of coenzyme Q, which is a sulfide quinone reductase cofactor \[[@B41]\]. It is worth noting that either exogenously supplied or endogenously produced H~2~S can be stored in the body in the form of bound sulfane, which is a reductant labile sulfur (e.g., persulfide (R-S-S-SH), polysulfide (RSS~n~SR), and protein-associated sulfur, among others) \[[@B42]\]. With regard to the dietary supplementation of H~2~S, garlic and garlic-derived organic polysulfides, such as diallyl trisulfide (DATS) and diallyl disulfide (DADS), behave as H~2~S donors with the aid of a biological thiol (e.g., glutathione), maintained via pentose phosphate pathway-mediated NADPH production \[[@B43]\].

2.4. Functional Roles of H~2~S in the Biological System {#sec2.4}
-------------------------------------------------------

H~2~S displays antioxidant effects through the direct quenching of reactive oxygen species (ROS) via a hydrosulfide anion (HS-), which is a powerful one-electron chemical reductant that is dissociated from H~2~S in physiological fluid \[[@B12]\]. H~2~S derivatives such as nitrosopersulfide, polysulfides, and dinitrososulfite may also be involved in redox switching in biological systems by generating redox congeners like nitroxyl, nitrous oxide, and sulfane sulfur \[[@B22]\]. NaHS may indirectly suppress ROS production through the H~2~S-mediated activation of a copper/zinc superoxide \[[@B44], [@B45]\]. In addition, H~2~S induces the suppression of oxidative stress through the activation of Nrf2 (transcription factor nuclear factor (erythroid-derived 2)-like 2) and NAD-dependent deacetylase sirtuin (SIRT)-3, resulting in increased expression of other antioxidant enzymes and proteins (e.g., GSH and thioredoxin-1) \[[@B46], [@B47]\]. The low concentration of H~2~S may cause oxidative stress, resulting in the depletion of tetrahydrobiopterin, which determines the levels of endothelial nitric oxide synthase (eNOS) activity \[[@B48]\]. As latent matrix metalloproteinases (MMPs) can be activated by oxidative stress \[[@B49]\], the antioxidant capacity of H~2~S may be involved, at least in part, in the suppression of MMP activation.

H~2~S is able to modulate the functions of proteins containing prosthetic metal complexes in acceptor proteins due to its high reactivity with metal ions \[[@B50], [@B51]\]. For example, polysulfides bind to inactive ferric indoleamine 2,3-dioxygenase (IDO1), which strongly suppresses the immune response, thereby reducing it to its oxygen-binding ferrous state, thus activating IDO1 to maximal turnover \[[@B52]\]. As such, H~2~S is able to elicit an anti-inflammatory response through the activation of IDO1. H~2~S can lead to protein S-sulfhydration (sulfuration or persulfidation) by covalently converting the -SH group of cysteine into an -SSH group in the protein \[[@B53]\], thereby altering the activities of various enzymes, including that of F~1~F~0~-ATPase \[[@B54]\], the ATP-sensitive potassium (K~ATP~) channel \[[@B55]\], and the phosphatase and tensin homolog (PTEN) \[[@B56]\]. In addition, protein sulfhydration changes the localization and stability of proteins inside cells and increases the resistance of proteins to oxidative stresses \[[@B54], [@B55]\]. H~2~S can activate soluble guanylyl cyclase (sGC) via direct heme binding \[[@B57]\] or by the inhibition of the cGMP phosphodiesterase (PDE) activity \[[@B57]\], resulting in the activation of cyclic GMP (cGMP)--protein kinase G (PKG) pathways.

The bioavailability of H~2~S may play an important role in the integrated stress response, that is, in coping with changes to the cellular environment \[[@B58], [@B59]\]. H~2~S transiently increases the phosphorylation of eukaryotic initiation factor 2 (eIF2*α*) via the inhibition of protein phosphatase-1 (PP1c) via H~2~S-driven persulfidation \[[@B59]\], thereby inducing a transient adaptive reprogramming of global mRNA translation independent of upstream kinases \[[@B59]\]. As an epigenetic modulator, H~2~S can modify the expression of Brahma-related gene 1 (Brg1) at the promoter region, thus suppressing the transcriptional activity of the ATP-dependent chromatin remodeling complex \[[@B60]\]. This suppressive activity of H~2~S in the expression of Brg1 contributes to the inhibition of vascular smooth muscle cell proliferation \[[@B60]\]. H~2~S may be involved in the decrease of the lysine acetylation of enzymes involved in fatty acid *β*-oxidation and glucose oxidation in diabetic conditions, thereby exerting a beneficial effect on cardiac energy substrate utilization by favoring a switch from fatty acid oxidation to glucose oxidation \[[@B61]\].

Mitochondrial damage associated with cardiovascular pathological stimuli, including oxidative stress, the over-activation of the renin-angiotensin-aldosterone and adrenergic systems, and the dysfunction of growth hormones, plays a central role in the loss of ischemic, and even nonischemic, cardiomyocytes \[[@B62], [@B63]\]. The levels of mitochondrial DNA (mtDNA) content are dramatically reduced in CSE gene-knockout mice; however, this reduction can be reversed via the exogenous delivery of H~2~S \[[@B64]\]. H~2~S can induce the replication of mtDNA and mitochondrial biogenesis by suppressing the methylation of mitochondrial transcription factor A (TFAM) \[[@B64]\]. In a different way, H~2~S may be involved in the stimulation of cardiac mitochondrial biogenesis through the activation of the 5′ AMP-activated protein kinase (AMPK)-peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1*α*) pathway \[[@B65]\]. The sulfhydration of AMPK and protein phosphatase 2A (PP2A), which leads to the activation of AMPK and the inhibition of PP2A, respectively, has been suggested as a mechanism that may be involved in the H~2~S-mediated stimulation of mitochondrial biogenesis under nonstressed conditions \[[@B65]\].

3. Myocardial Fibrosis and Antifibrosis Potential of H~2~S {#sec3}
==========================================================

3.1. Myocardial Fibrosis {#sec3.1}
------------------------

The heart is a highly organized structure composed of cardiomyocytes and noncardiomyocytes such as fibroblasts (nonexcitable cells of mesenchymal origin), endothelial cells, and vascular smooth muscle cells \[[@B66], [@B67]\]. Maladaptive crosstalk between cardiomyocytes and noncardiomyocytes responding to pathological stress may result in myocardial fibrosis, adverse remodeling, and arrhythmogenesis. Myocardial fibrosis is a reparative process involving the restoration of cardiomyocytes from cell death or sustained stress and is involved in maintaining the integrity of the heart, an action exerted mainly by the fibrillar, collagen-rich extracellular matrix (ECM), in the short term \[[@B68]\]. However, reactive fibrosis, such as interstitial and perivascular fibrosis \[[@B69]\], contributes to the progressive architectural remodeling of the heart as a result of the formation and deposition of excess fibrous connective tissue \[[@B70]\]. RAAS, transforming growth factor-*β* (TGF-*β*), and *β*-adrenergic systems are common contributors to cardiac remodeling. These systems are connected to each other in an auto-/paracrine manner as a part of a larger signaling network \[[@B71]\]. During the progression of myocardial fibrosis, various distinct immunological and molecular mechanisms are interconnected via interactions between various cells, including macrophages, myofibroblasts, and matrices \[[@B68], [@B70], [@B72], [@B73]\]. As depicted in [Figure 2](#fig2){ref-type="fig"}, the loss of cardiomyocytes driven by various injurious agents and stresses has a detrimental effect on the architecture and function of the heart due to the negligible regenerative capacity of the heart, especially with regard to cardiomyocytes \[[@B72], [@B74]\]. Inflammatory cells, such as macrophages, appear in damaged regions of the heart and are tasked with removing the necrotic cardiomyocyte debris. TGF-*β* is the best-known fibrogenic growth factor involved in cardiac fibrosis, even though a baseline level of TGF-*β* signaling or an early-responsive increase in TGF-*β* may protect the heart from acute injury \[[@B75]\]. It has been demonstrated that angiotensin-II (Ang-II) is an important mediator of cardiac fibrosis, working with the TGF-*β* in the fibrotic response, due to the coexistence of TGF-*β* receptors and Ang-II receptors in cardiomyocytes, inflammatory cells, and cardiac fibroblasts. TGF-*β*1 triggers the appearance of inflammatory cells and myofibroblasts at the site of injury \[[@B75], [@B76]\] and stimulates the deposition of ECM, including fibronectin, fibrillar collagen types I and III, and proteoglycans. During this initial stage, in addition to the production of inflammatory cytokines, inflammatory cells secrete Ang-I, which is converted to Ang-II via the action of ACE. Ang-II plays a pivotal role in stimulating TGF-*β* production, prompting the proliferation of circumambient fibroblasts and their transdifferentiation into myofibroblasts. The pool of fibroblasts can be enlarged by the transformation of either circulating bone marrow cells or endothelial/epithelial cells into fibroblasts \[[@B66], [@B77]\]. During the proliferative phase of cardiac repair, fibroblasts undergo transdifferentiation into contractile myofibroblasts, secreting large amounts of matrix proteins, such as collagens \[[@B66]\]. Then, the scar tissue matures with the formation of a collagen-based matrix \[[@B78]\], where the removal of myofibroblasts is controlled by unknown endogenous stop signals in order to restrain the fibrotic response \[[@B78]\]. However, a clear mechanistic view of phenotype and heterogeneity of cardiac fibroblasts in the process of fibrosis has yet to be fully established \[[@B77]\]. In terms of the underlying molecular mechanisms involved in the progression of fibrosis, several pathways, including the TGF-*β*, JNK/p38, PI3K/AKT, WNT/*β*-catenin, and Ras-Raf- mitogen-activated protein kinase- (MEK-) extracellular signal-activated kinase (ERK) pathways, have been identified \[[@B79]\]. Involved in canonical fibrotic signaling, TGF-*β* induces the nuclear translocation of the complex known as "mothers against decapentaplegic homolog," or SMAD complex promoting fibrosis. In noncanonical signaling, TGF-*β* signaling induces SMAD-independent pathways, including the PI3K/AKT and mitogen-activated protein kinase (MAPK) pathways, nuclear factor kappa light chain enhancer of activated B cell (NF-*κβ*), RHO/RAC1, and CDC42 \[[@B75]\]. Interestingly, it has been suggested that, if supplied in a timely manner, H~2~S can suppress TGF-*β*1-induced transdifferentiation from fibroblasts to myofibroblasts via the inhibition of SMAD3 activation in human fibroblast cells \[[@B80]\].

3.2. Antifibrosis Potential of H~2~S {#sec3.2}
------------------------------------

### 3.2.1. Myocardial Infarction {#sec3.2.1}

Extensive necrosis of cardiomyocytes in infarcted hearts not only triggers a strong inflammatory response but also induces interstitial and perivascular fibrosis due to geometrical, biomechanical, and biochemical changes in the uninjured ventricular wall \[[@B69]\]. During cardiac injury and hypertrophic remodeling, the production of inflammatory signaling molecules, such as tumor necrosis factor-*α* (TNF-*α*), interleukin (IL)-1*β*, and IL-6, can contribute to hypertrophic and fibrotic responses. Interestingly, ischemia causes a significant reduction in the levels of H~2~S associated with decreased expression of CSE, which is an H~2~S-synthesizing enzyme under the control of the miRNA-30 family \[[@B16]\]. Moreover, it has been suggested that reduced plasma H~2~S levels are correlated with the severity of coronary heart disease \[[@B81]\]. Similar to the cardioprotective role of NO \[[@B82]--[@B84]\], various signaling pathways from different types of exogenous H~2~S may be involved in the suppression of MI-associated fibrosis ([Table 1](#tab1){ref-type="table"}). These pathways include GSK-3*β*/*β*-catenin \[[@B85]\], cGMP-PKG \[[@B86]\], Nrf2 \[[@B87]--[@B89]\], miRNA signaling pathways \[[@B16], [@B90], [@B91]\], and the protection of mitochondria \[[@B92]--[@B95]\]. Although postconditioning only exerts cardioprotection in young hearts, exogenous H~2~S restores postconditioning benefits by upregulating autophagy via the activation of the AMPK/mammalian target of rapamycin (mTOR) pathway in the aged hearts and cardiomyocytes \[[@B96]\]. It is unclear whether the signaling pathways identified share common contributors derived from H~2~S, or whether this is simply the result of experimental settings targeting different signaling pathways. Therefore, the identification of a unique contributor of H~2~S involved in the suppression of MI-mediated myocardial fibrosis is necessary.

### 3.2.2. Hypertension {#sec3.2.2}

Hypertension increases oxidative stress, vascular inflammation, and vascular remodeling, such as in the case of fibrosis \[[@B97]\]. The antihypertensive effects of H~2~S, associated with its modulation of various levels of channel activity and cGMP-PKG pathways, may contribute to the suppression of fibrosis caused by hypertension \[[@B98]--[@B101]\]. As presented in [Table 1](#tab1){ref-type="table"}, H~2~S supplementation under hypertensive conditions may suppress myocardial fibrosis via the modulation of several different signaling pathways. It is worth noting that H~2~S can inhibit ACE via the binding of zinc ions to the active center of ACE \[[@B102]\]. It has been postulated that the H~2~S-mediated suppression of ACE may indirectly contribute to vasorelaxation and the suppression of the Ang-II-mediated transition of fibrosis. Alternatively, the suppression of inflammation \[[@B103]\] and the reduction of cardiomyocyte death from oxidative stress \[[@B104]\], as well as the activation of eNOS/NO pathway \[[@B105]\], are likely to have antifibrosis roles with regard to H~2~S under hypertensive conditions. Interestingly, it has been noted that local delivery of H~2~S can lower systemic blood pressure. For example, the intra-cerebroventricular (ICV) infusion of NaHS in both spontaneous and Ang-II-induced hypertensive rat models was found to decrease the mean arterial blood pressure and heart rate during ICV infusions \[[@B106]\]. Moreover, H~2~S secreted from periadventitial adipose tissue has been previously found to contribute to blood pressure homeostasis \[[@B107]\].

### 3.2.3. Diabetes {#sec3.2.3}

The metabolic environment of diabetes, including hyperglycemia, hyperlipidemia, and oxidative stress, causes cardiomyocyte cell death. The early stages of diabetic remodeling of the heart are usually asymptomatic, such that myocardial changes mostly occur at the molecular level. In the middle stage of remodeling, progressive cardiomyocyte hypertrophy and myocardial fibrosis result in impaired ejection fraction \[[@B108]\]. In patients with diabetes, as well as in streptozotocin- (STZ-) treated rats, lowered circulating levels of H~2~S due to the downregulated expression of H~2~S-synthesizing enzymes have been frequently found \[[@B109]--[@B111]\]. As depicted in [Table 1](#tab1){ref-type="table"}, several underlying mechanisms of H~2~S involve the suppression of myocardial fibrosis in diabetic rats via (1) the suppression of the TGF-*β*1/SMAD3 pathway \[[@B110], [@B112], [@B113]\] and canonical Wnt pathway \[[@B114]\], (2) the suppression of endoplasmic reticulum stress \[[@B19], [@B115]\], (3) the downregulation of the JAK/STAT signaling pathway \[[@B110]\], and (4) the regulation of autophagy \[[@B112], [@B116]\]. Although it has not yet been clearly elucidated, there is a possibility that H~2~S may be involved in the modulation of ECM remodeling via miRNA or other transcription machinery affecting the expression of ECM-processing enzymes in diabetes. For example, H~2~S has been found to attenuate fibrotic changes in diabetic kidneys via the downregulation of miRNA-194, which plays an important role in the modulation of proteins involved in collagen realignment \[[@B117]\].

### 3.2.4. Neurohormonal Overstimulation {#sec3.2.4}

The activation of the *β*-adrenergic nervous system and RAAS has been commonly found in fibrotic HF patients, and *β*-blockers and RAAS inhibitors have been suggested as a first-line treatment to correct the underlying cardiac dysfunction and reduce morbidity \[[@B7], [@B118]\]. The overstimulation of *β*-adrenoceptor may result in the impairment of the negative modulation of H~2~S on the *β*-adrenoceptor system, resulting in a calcium overload, leading to the impairment of cardiac contractility and, ultimately, to cardiomyocyte death \[[@B119]\]. Exogenous H~2~S supplementation inhibits isoprenaline- (ISO-) induced cardiac hypertrophy depending on SIRT3, which is predominantly localized in the mitochondria, and may be associated with antioxidant properties \[[@B120]\]. Other signaling pathways, including reducing NADPH oxidase \[[@B121]\] or S-sulfhydration of Ca^2+^/calmodulin-dependent protein kinase II \[[@B122]\], have been associated with the antifibrosis role of H~2~S under conditions of *β*-adrenoceptor overstimulation. Mast cells will infiltrate into the heart at the site of inflammation and serve as a local source of renin in cardiovascular tissues. H~2~S may benefit from the action of renin secreted from mast cells \[[@B123]\]. In view of hormone-associated myocardial fibrosis, the excessive generation of thyroxine from thyroid induces thyrotoxicosis and affects the cardiovascular system, resulting in the symptoms of hypertension, arrhythmia, and cardiac hypertrophy \[[@B124]\]. Under conditions of excessive thyroxine, H~2~S may bolster rat myocardial fibrosis through the activation of autophagy mediated by the PI3K/AKT signaling pathway and via the downregulation of miRNA-21, miRNA-34a, and miRNA-214 expression \[[@B125]\].

4. Summary and Perspectives {#sec4}
===========================

Currently, strategies for the treatment of established HF are focused on relieving the symptoms and signs of HF, such as treating edema, preventing hospital admission, and improving survival \[[@B6]\]. Myocardial fibrosis determines the clinical course of heart dysfunction and can eventually lead to heart failure. A substantial amount of research has been dedicated to the identification of HF target(s) to improve the diagnosis and treatment of fibrotic pathways with organ specificity. Myocardial fibrosis has many steps and usually involves several pathways. Complex networks of molecular signaling, including GSK-3*β*, *β*-catenin, and TGF-*β*1/SMAD3, have been implicated in the initiation, progression, and regression of myocardial fibrosis \[[@B1]--[@B5]\]. The targeting of collagen fibrillogenesis should be performed with caution as collagen turnover is a common process in most tissues whose effects can be detrimental \[[@B150]\]. Although TGF-*β*1 is a central profibrogenic cytokine and a critical contributor during myocardial fibrosis, treatment with TGF-*β* antibody has been found to result in an increased mortality rate and poor MI-associated ventricular remodeling in a mouse model \[[@B151]\]. Although SMAD3 and TNF-*α* signaling play a fundamental role in fibrosis progression, the targeting of SMAD3 and TNF-*α* antagonism has not yet been found to provide a successful antifibrosis outcome \[[@B151]\]. Based on the important role of Ang-II in the initiation of myocardial fibrosis, the antagonism of the angiotensin pathway via ACE inhibitors and angiotensin receptor antagonists is considered to be a useful approach for the management of fibrotic diseases. Recently, AMPK*α* activators (e.g., metformin) have been found to be a promising therapeutic target for fibrosis \[[@B152]\]. Myocardial fibrosis is not caused by a single profibrotic pathway but is rather associated with the activation of several profibrotic pathways, including immunological and molecular mechanisms \[[@B70]\]. It is also worth noting that a combined antifibrotic strategy, including inflammatory mediators, profibrotic cytokines, and epigenetic and cell and/or tissue intrinsic changes, has been suggested as a possible method for the successful treatment of myocardial fibrosis \[[@B7], [@B70]\].

As briefly addressed in this review, H~2~S possesses antioxidant capacities and modulates various signaling pathways, including the activation of cGMP-PKG pathways, the posttranslational modification of proteins, metal-binding (including heme), and mitochondrial respiratory control \[[@B9]\]. In addition, H~2~S may serve as a fine-tuner of mitochondrial homeostasis and the autophagic process in the physiology and pathophysiology of the cardiovascular system \[[@B153]\]. Moreover, H~2~S is involved in antiapoptosis of cardiomyocytes, anti-inflammation, antihypertension, and other beneficial cardiovascular processes \[[@B154], [@B155]\]. As a timely response to energy stress, autophagy is a bulk degradation/recycling system that is tightly controlled by the homeostatic pathway in the cardiovascular system \[[@B153], [@B156]\]. Despite the existence of conflicting opinions on the beneficial and harmful effects of autophagy, disturbances in the autophagic process have been found in various forms of HF, including age-related cardiomyopathies \[[@B156]\]. H~2~S may be involved in the regulation of autophagy by either suppressing or enhancing the signaling pathways that contribute to the attenuation of myocardial fibrosis, as reviewed in a previous paper \[[@B156], [@B157]\]. Although it is still currently under investigation, numerous findings have demonstrated that H~2~S may be involved in the suppression of myocardial fibrosis caused by (1) myocardial infarction, (2) hypertension, (3) STZ-induced diabetes, and (4) the overstimulation of neurohormonal routes ([Table 1](#tab1){ref-type="table"}). The signaling pathways mediated by H~2~S may converge on the suppression of myocardial fibrosis that occurs as a result of various stresses, as shown in [Figure 2](#fig2){ref-type="fig"} and [Table 1](#tab1){ref-type="table"}. It is unclear whether target pathways modulated by the action of H~2~S work independently of each other; however, it is most important to determine whether they allow for the merging of multiple pathways into a single antifibrosis signaling cascade. Versatile mechanisms and signaling pathways triggered by H~2~S have already been identified, as briefly shown in this review. In this context, it appears that H~2~S is emerging as a new type of myocardial fibrosis suppressor. However, it is necessary to identify the molecular target or specific signaling pathway that is under the control of H~2~S in a direct and specific manner during myocardial fibrosis. It remains to be clearly established whether H~2~S can directly control the cells involved in fibrosis (e.g., cardiomyocytes, fibroblasts, and inflammatory cells) and ECM deposition.

The advances being made in H~2~S biology are a promising tool for the future development of medicines for the treatment of myocardial fibrosis based on H~2~S, as well as multitarget molecules able to release H~2~S \[[@B158]\]. There is currently a lack of fibrosis-specific biomarkers that can be used to determine the stage and grade of myocardial fibrosis, as well as for the identification of patients who may benefit from a specific type of therapy. In addition to the development of new techniques for evaluating the stage and/or severity of myocardial fibrosis \[[@B159]\], a new strategy for reversing preexisting fibrosis using H~2~S could be a valuable approach. Moreover, the potential of H~2~S in preventing or repairing cardiomyocyte loss via the stimulation of cardiac stem cells or transdifferentiation from noncardiomyocytes to cardiomyocytes needs to be critically evaluated in future studies \[[@B160]\]. It is worth mentioning that H~2~S can have serious and toxic effects at high concentrations or high release rates, including sudden unconsciousness and death \[[@B14], [@B161]\]. Therefore, the optimal concentration or dose of H~2~S for the desired antifibrosis effect needs to be critically examined. Additionally, for the therapeutic potential of H~2~S, pharmacological agents that generate or release H~2~S need to be adequately harnessed for the delivery of physiologically relevant concentrations in a safe manner. Considering that myocardial fibrosis is a long-term consequence of heart disease, the study of dietary supplements that are able to supply H~2~S safely or boost H~2~S synthesis is needed for the management of myocardial fibrosis. The long-term consequences and clinical benefits of H~2~S against myocardial fibrosis should also be investigated in the future. In addition, the study of the H~2~S-mediated the study of the H~2~S-mediated reversal of myocardial fibrosis could prove to be advantageous in clinical studies.
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![Endogenous H~2~S production. Abbreviations: CAT: cysteine aminotransferase; CBS: cystathionine-*β*-synthase; CSE: cystathionine-*γ*-lyase; ETHE-1: persulfide dioxygenase; GSSH: oxidized glutathione; MST: 3-mercaptopyruvate sulfurtransferase; Rhod: rhodanase; SOx: sulfur dioxygenase; SQR: sulfide quinone oxidoreductase.](OMCL2020-4105382.001){#fig1}

![Simplified process of myocardial fibrosis and possible antifibrosis roles of H~2~S. Abbreviations: Ang-II: angiotensin-II; ECM: extracellular matrix; H~2~S: hydrogen sulfide; TGF-*β*: transforming growth factor-*β*.](OMCL2020-4105382.002){#fig2}

###### 

H~2~S donors and their involvement in myocardial fibrosis.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  H~2~S donor (characteristics)                                                                      Fibrosis model                                                          Suggested mode of action
  -------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------- ----------------------------------------------------------------------
  Sodium thiosulfate (Na~2~O~3~S)\                                                                   Hypertension                                                            Antihypertensive activity \[[@B99]\]\
  (Hydrophilic, fast H~2~S release)                                                                                                                                          ↓Oxidative stress and ↑endogenous H~2~S production \[[@B126]\]

                                                                                                                                                                             

  Sodium hydrosulfide (NaHS)\                                                                        Diabetes (type I)                                                       ↓Canonical Wnt pathway-TGF-*β*1/SMAD3 pathway \[[@B114]\]\
  (Hydrophilic, fast H~2~S release)                                                                                                                                          ↑PKC-ERK1/2MAPK signaling pathway \[[@B127]\]\
                                                                                                                                                                             ↓ER stress \[[@B115]\]\
                                                                                                                                                                             ↓Autophagy via the upregulation of the PI3K/AKT1 pathway \[[@B116]\]

  Diabetes (type II)                                                                                 ↓Cardiac muscle degradation via sulfhydration of MuRF1 \[[@B128]\]      

  Hypertension                                                                                       ↓Inflammatory response \[[@B103]\]\                                     
                                                                                                     ↓Extracellular matrix accumulation and ↑vascular density \[[@B129]\]\   
                                                                                                     ↓Nox4-ROS-ERK1/2 pathway and ↑HO-1 expression \[[@B130]\]\              
                                                                                                     ↑Akt/eNOS/NO pathway \[[@B105]\]\                                       
                                                                                                     ↓Nitrotyrosine, ↓MMP-2 and MMP-9, and ↑TIMP-1 and TIMP-3 \[[@B131]\]\   
                                                                                                     ↑Opening of K~ATP~ channels and ↓oxidative stress \[[@B132]\]           

  Myocardial infarction                                                                              ↓Oxidative stress \[[@B133]\]\                                          
                                                                                                     ↓iNOS and ↑HO-1 expression \[[@B134]\]\                                 
                                                                                                     ↓mPTP opening in the aging cardiomyocytes \[[@B92]\]\                   
                                                                                                     ↑Glycogen synthase kinase-3*β*/*β*-catenin pathway \[[@B85]\]\          
                                                                                                     ↑cGMP-dependent PKG/phospholamban pathway \[[@B135]\]\                  
                                                                                                     ↑Angiogenesis \[[@B136]\]\                                              
                                                                                                     ↑Autophagy in the aged hearts \[[@B96]\]                                

  Metal toxicity\                                                                                    ↓Sp1 transactivation and ↓TGF-*β*1/SMAD1 pathway \[[@B21]\]             
  (e.g., nickel)                                                                                                                                                             

                                                                                                                                                                             

  Sodium sulfide (Na~2~S) (Hydrophilic, H~2~S release for \~520 min *in vivo*; \~5 min *in vitro*)   Hypertension                                                            ↑Vasorelaxation \[[@B100], [@B101]\]\
                                                                                                                                                                             ↑Trx1 \[[@B137]\]

  Myocardial infarction                                                                              ↑Mitochondrial function \[[@B95]\]\                                     
                                                                                                     ↑Nrf2 signaling pathway \[[@B87]\]\                                     
                                                                                                     ↑miR-21 \[[@B91]\]                                                      

                                                                                                                                                                             

  GYY4137\                                                                                           Diabetes (type I)                                                       ↓FoxO1 pathway \[[@B138]\]\
  (Hydrolysis-triggered H~2~S release; slow-release and 3--4 h lasting)                                                                                                      ↑Autophagy via the AMPK/mTOR pathway \[[@B112]\]\
                                                                                                                                                                             ↑Nrf2 pathway mediated by sulfhydration of Keap1 \[[@B88]\]

  Myocardial infarction                                                                              ↑PKG I \[[@B139]\]\                                                     
                                                                                                     ↓Oxidative stress and ↓apoptosis \[[@B140], [@B141]\]                   

                                                                                                                                                                             

  AP67/AP72\                                                                                         Atherosclerosis                                                         ↓Calcification effects in heart valves \[[@B142]\]
  (Slow-releasing H~2~S donors)                                                                                                                                              

                                                                                                                                                                             

  AP39\                                                                                              Myocardial infarction                                                   ↓mPTP opening \[[@B93], [@B94]\]\
  (Mitochondria-targeted H~2~S)                                                                                                                                              ↓Cardiomyocyte death and ↓inflammatory response \[[@B143]\]

  SG-1002\                                                                                           Hypertension                                                            ↑VEGF-Akt-eNOS-NO-cGMP signaling pathway \[[@B144]\]
  (Orally active)                                                                                                                                                            

  Myocardial dysfunction                                                                             ↑Adiponectin-AMPK signaling and ↓ER stress \[[@B19]\]                   

  ↑NO bioavailability \[[@B145]\]                                                                                                                                            

                                                                                                                                                                             

  Diallyl disulfide (DAD) \[[@B146]\]\                                                               Myocardial infarction                                                   ↓ER stress via SIRT1 \[[@B147]\]\
  (Organosulfur compound; insoluble in water; slow H~2~S donor \[[@B146]\])                                                                                                  ↑AMPK-mediated AKT/GSK-3*β*/HIF-1*α* activation \[[@B148]\]

                                                                                                                                                                             

  Diallyl trisulfide (DAT) \[[@B146]\]\                                                              Hyperglycemia                                                           ↑PI3K/Akt/Nrf2 pathway \[[@B89]\]\
  (Organosulfur compound; fast H~2~S donor)                                                                                                                                  ↓JNK/NF-*κβ* pathway \[[@B149]\]

                                                                                                                                                                             

  ADT-OH\                                                                                            Myocardial infarction                                                   ↑Autophagic flux via activating AMPK \[[@B94]\]
  (H~2~S-aspirin hybrid molecule)                                                                                                                                            

                                                                                                                                                                             

  ZYZ-803\                                                                                           Adrenergic overload                                                     ↑Activation of VEGF/cGMP pathway \[[@B86]\]
  (H~2~S-NO hybrid molecule)                                                                                                                                                 

                                                                                                                                                                             

  ZYZ-802\                                                                                           Hypertension                                                            ↓Oxidative stress and ↓cardiomyocyte death \[[@B104]\]
  (S-Propargyl-cysteine; cysteine derivatives)                                                                                                                               

  Myocardial infarction                                                                              ↓miRNA-30 family \[[@B16]\]                                             
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: AMPK: AMP-activated protein kinase; Ang-II: angiotensin-II; cGMP: cyclic guanosine monophosphate; ECM: extracellular matrix; eNOS: endothelial nitric oxide synthase; ER: endoplasmic reticulum; ERK: extracellular-signal-regulated kinase; FoxO1: transcription factor Forkhead 1; GSK-3*β*: glycogen synthase kinase-3*β*; H~2~S: hydrogen sulfide; HIF-1*α*: hypoxia-inducible factor-1*α*; HO-1: heme oxygenase-1; iNOS: inducible nitric oxide synthase; JNK: c-Jun N-terminal kinase; Keap1: Kelch-like ECH-associated protein 1; MAPK: mitogen-activated protein kinase; MI: myocardial infarction; miRNA: microRNA; MMP: matrix metalloproteinase; mPTP: mitochondrial permeability transition pore; NOX4: NADPH oxidase 4; MuRF1: muscle RING-finger protein-1; NF-*κβ*: nuclear factor kappa light chain enhancer of activated B cell; Nrf2: nuclear factor E2-related factor 2; PI3K: phosphoinositide 3-kinases; PKC: protein kinase C; PKG: protein kinase G; SIRT1: sirtuin 1; SMAD: mothers against decapentaplegic homolog; Sp1: specificity protein 1; TGF-*β*: transforming growth factor-*β*; TIMP: tissue inhibitor of metalloproteinase; Trx1: thioredoxin 1; VEGF: vascular endothelial growth factor. ↓ and ↑ denote inhibition or suppression and increase or activation, respectively.

[^1]: Guest Editor: Mario Fontana
